Details

Autor(en) / Beteiligte

• Yoo, Jeong Rae
• Lee, Keun Hwa
• Kim, Misun
• Oh, Hyun Joo
• Heo, Sang Taek

Titel

Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome

Ist Teil von

• International journal of infectious diseases, 2022-09, Vol.122, p.656-658

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• •The rising incidence of SFTS poses a risk to public health•SFTS has a high fatality rate and there are currently no effective treatments•Administration of single dose tocilizumab in a patient with SFTS improved symptoms•Tocilizumab can be used to treat non-fatal SFTS We report the administration of an anti-interleukin (IL)-6 antibody in a case of severe fever with thrombocytopenia syndrome (SFTS) with an increase in IL-6. On the day of admission, SFTS viral load and IL-6 concentration were 93 831 copies/ml and 5.4 pg/ml, respectively, and tocilizumab was administered. SFTS viral load decreased to 17 821.1 copies/ml on the 3rd day of admission, while IL-6 levels increased to 104.9 pg/ml; SFTS viral load and IL-6 levels had decreased to 2876.4 copies/ml and 48.2 pg/ml on 7th day of admission, respectively. The patient fully recovered no tocilizumab adverse events.